INTERIM REPORT
1 JANUARY – 30 JUNI 2022

We strive to improve people's lives

SEK
2079
m

NET SALES

SEK
240
m

EBITA

10
%

EARNINGS GROWTH
EBITA R12 MONTHS

74
%

P/WC

Kristina Willgård

A quarter in change!

Just as expected, sales of COVID-19-related products have declined sharply compared to the corresponding quarter last year, when it was on record level. Growth is instead attributable to the acquisitions in Europe in recent years, as well as to the segments that reported weaker growth during the pandemic. 

A leading player in Life Science

AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.

Acquisitions during the interim period

During the interim period, four acquisitions have been completed and after the end of the interim period, another acquisition was completed. These  acquisitions are estimated to contribute with annual net sales of approximately SEK 855m and approximately 350 employees.

Forvarv Onepage